AstraZeneca (LON: AZN) shares are gaining ground on Tuesday after the company and Merck & Co (NYSE: MRK) announced that Japan has approved Lynparza to treat advanced ovarian, prostate and pancreatic cancers.
The companies said the approvals for the three cancer types authorise Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated castrate-resistant prostate cancer with distant metastasis; and as a maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
The Japanese Ministry of Health, Labour and Welfare approvals are based on positive results from the PAOLA-1, PROfound and POLO Phase 3 trials.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Dave Fredrickson, AstraZeneca’s Executive Vice President of its Oncology Business Unit said that the approvals “further underline the critical importance of biomarker testing at diagnosis, which helps physicians determine a course of treatment tailored to individual patients to substantially delay disease progression.”
In London, AstraZeneca shares are trading 4.51% higher at 7549p following the previous days close at 7223p.